The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks

Wang, Juan; Du, Lingyao; Zhu, Xia; Chen, En‐Qiang; Tang, Hong

doi:10.4103/0255-0857.148827

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that HBeAg titer < 0.8 lg PEIU/mL combined with its declined value > 0.84 lg PEIU/mL at 12-wk predicted VR after 96-wk LAM and ADV optimized therapy with a sensitivity, specificity, PPV, NPV of 71%, 91%, 91% and 71%, respectively, and accompanied with an AUROC of 0.812. In addition, although some studies indicated that the on-treatment HBeAg level or declined value at 24-wk was a predictor for NAs treatment response[9,12], the sample size was small or HBeAg was detected using a semi-quantitative method which cannot accurately quantify HBeAg level, thus limited the validity of the prediction. For example, Zhang et al[12] detected serum HBeAg semi-quantitatively and found that the on-treatment declined value of HBeAg (> 65%) at 24-wk was the best predictor for treatment response (HBeAg seroconversion and accompanied by undetectable serum HBV DNA) after 96-wk ETV therapy, and the PPV, NPV, AUROC was 83.3%, 93.6% and 0.885, respectively.…”

Section: Discussionmentioning

confidence: 99%

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

Gao

Meng

Zhang

et al. 2016

WJH

View full text Add to dashboard Cite

AIMTo investigate potential predictors for treatment response to nucleos(t)ide analogues (NAs) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients.METHODSSeventy-six HBeAg-positive CHB patients received 96-wk NAs optimized therapy (lamivudine and adefovir dipivoxil) were studied retrospectively. Serum hepatitis B surface antigen, HBeAg, hepatitis B core antibody, hepatitis B virus (HBV) DNA and alanine aminotransferase levels were quantitatively measured before and during the treatment at 12 and 24 wk. Stepwise logistic regression analyses were performed to identify predictors for treatment response, and areas under the receiver operating characteristic curves (AUROC) of the independent predictors were calculated.RESULTSForty-three CHB patients (56.6%) achieved virological response (VR: HBV DNA ≤ 300 copies/mL) and 15 patients (19.7%) developed HBeAg seroconversion (SC) after the 96-wk NAs treatment. The HBeAg level (OR = 0.45, P = 0.003) as well as its declined value (OR = 2.03, P = 0.024) at 24-wk independently predicted VR, with the AUROC of 0.788 and 0.736, respectively. The combination of HBeAg titer < 1.3 lg PEIU/mL and its decreased value > 1.6 lg PEIU/mL at 24-wk predicted VR with a sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of 85%, 100%, 100% and 83%, respectively, and the AUROC increased to 0.923. The HBeAg level (OR = 0.37, P = 0.013) as well as its declined value (OR = 2.02, P = 0.012) at 24-wk also independently predicted HBeAg SC, with the AUROC of 0.828 and 0.814, respectively. The HBeAg titer < -0.5 lg PEIU/mL combined with its declined value > 2.2 lg PEIU/mL at 24-wk predicted HBeAg SC with a sensitivity, specificity, PPV, NPV of 88%, 98%, 88% and 98%, respectively, and the AUROC reached 0.928.CONCLUSIONThe combination of HBeAg level and its declined value at 24-wk may be used as a reference parameter to optimize NAs therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

Gao

Meng

Zhang

et al. 2016

WJH

View full text Add to dashboard Cite

show abstract

“…Previous studies have identified the association between pretreatment alanine aminotransferase (ALT), HBV DNA, hepatitis B surface antigen (HBsAg), quantitative HBeAg (qHBeAg), platelets (PLT), gamma-glutamyl transpeptidase (GGT), and quantitative anti-hepatitis B core antibody (qAnti-HBc) levels with HBeAg seroconversion (Chi et al, 2015;Fan et al, 2016;Fried et al, 2008;Li et al, 2014;Wang et al, 2015a;Hou et al, 2015;Huang et al, 2015). Although several clinically useful models have been established for assessing HBeAg seroconversion, they require complex calculations or concentrate on the response to interferon (Wang et al, 2015b;Lee et al, 2014;Lee et al, 2011;Liu et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

Geng

Gao

et al. 2017

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B

Abdurakhmanov

Rozina

Nikulkina

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Materials and methods. We conducted an observational study in 101 chronic hepatitis B (HBeAg-negative and HBeAg-positive) patients treated (3 years) with entecavir, tenofovir or telbivudine. Results and discussion. Treatment with entecavir and tenofovir was associated with high rate of virologic and biochemical response (95%) and HBeAg seroconversion (93% and 67%, respectively). Cumulative rate of virologic resistance was 0; 3.1% and 43.5% for tenofovir, entecavir and telbivudine, respectively. Long-term nucleos(t)ide analogues treatment resulted in a regress of liver fibrosis (from 8.92 to 7.18 kPa, р0.0001) and reduction in the number of patients with advanced fibrosis (from 48.1% to 13.8%, р0.0001). Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases. Conclusion. Entecavir and tenofovir might be recommended for the treatment of chronic hepatitis B because of having potent antiviral effect, high genetic barriers against resistance and good safety.

show abstract

The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks

Cited by 3 publications

References 18 publications

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B

Contact Info

Product

Resources

About